首页 | 本学科首页   官方微博 | 高级检索  
检索        


Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Authors:Robert J Motzer MD  David F McDermott MD  Bernard Escudier MD  Mauricio Burotto MD  Toni K Choueiri MD  Hans J Hammers MD  PhD  Philippe Barthélémy MD  PhD  Elizabeth R Plimack MD  Camillo Porta MD  Saby George MD  Thomas Powles MD  Frede Donskov MD  PhD  Howard Gurney MD  Christian K Kollmannsberger MD  Marc-Oliver Grimm MD  Carlos Barrios MD  Yoshihiko Tomita MD  PhD  Daniel Castellano MD  Viktor Grünwald MD  PhD  Brian I Rini MD  M Brent McHenry PhD  Chung-Wei Lee MD  PhD  Jennifer McCarthy MA  Flavia Ejzykowicz PhD  Nizar M Tannir MD
Institution:1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;2. Division of Medical Oncology, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts;3. Department of Medical Oncology, Gustave Roussy, Villejuif, France;4. Bradford Hill Clinical Research Center, Santiago, Chile;5. Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts;6. Department of Medical Oncology, University of Texas Southwestern Kidney Cancer Program, Dallas, Texas;7. Medical Oncology, Strasbourg European Cancer Institute, Strasbourg, France;8. Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania;9. Department of Internal Medicine, University of Pavia, Pavia, Italy;10. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York;11. Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Center, Queen Mary University of London, Royal Free National Health Service Trust, London, United Kingdom;12. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark;13. Department of Medical Oncology, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia;14. Department of Medicine, British Columbia Cancer Agency, Vancouver, British Columbia, Canada;15. Department of Urology, Jena University Hospital, Jena, Germany;16. Oncology Research Unit, Saint Luke Hospital, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil;17. Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan;18. Medical Oncology Department, October 12th University Hospital, Cancer Network Biomedical Research Center, Madrid, Spain;19. Interdisciplinary Genitourinary Oncology, West German Cancer Center Clinic for Internal Medicine and Clinic for Urology, University Hospital Essen, Essen, Germany;20. Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee;21. Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey;22. Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey;23. Department of Clinical Scientists, Bristol Myers Squibb, Princeton, New Jersey;24. Department of Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey;25. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Abstract:
Keywords:advanced renal cell carcinoma  CheckMate 214  dual checkpoint inhibition  durable response  long-term follow-up  nivolumab plus ipilimumab  phase 3
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号